Shocking HIV-1 with immunomodulatory latency reversing agents [PDF]
Seminars in Immunology, 2021 The "shock-and-kill" strategy is one of the most explored HIV-1 cure approaches to eliminate latent virus. This strategy is based on HIV-1 reactivation using latency reversing agents (LRAs) to reactivate latent proviruses (the "shock" phase) and to induce subsequent elimination of the reactivated cells by immune responses or virus-induced cytopathic ...
Anna Kula-Pacurar +2 more
exaly +7 more sources
Optimal Control of an HIV Model with Gene Therapy and Latency Reversing Agents [PDF]
Mathematical and Computational Applications, 2021 In this paper, we study the dynamics of HIV under gene therapy and latency reversing agents. While previous works modeled either the use of gene therapy or latency reversing agents, we consider the effects of a combination treatment strategy.
Zachary Abernathy +3 more
doaj +3 more sources
The Current Status of Latency Reversing Agents for HIV-1 Remission [PDF]
Annual Review of Virology, 2021 Combinatory antiretroviral therapy (cART) reduces human immunodeficiency virus type 1 (HIV-1) replication but is not curative because cART interruption almost invariably leads to a rapid rebound of viremia due to the persistence of stable HIV-1-infected cellular reservoirs.
Anthony Rodari, Gilles Darcis
exaly +5 more sources
Epigenetic Regulation of HIV-1 Sense and Antisense Transcription in Response to Latency-Reversing Agents. [PDF]
Noncoding RNA, 2023 Nucleosomes positioned on the HIV-1 5′ long terminal repeat (LTR) regulate sense transcription as well as the establishment and maintenance of latency. A negative-sense promoter (NSP) in the 3′ LTR expresses antisense transcripts with coding and non-coding activities. Previous studies identified cis-acting elements that modulate NSP activity.
Li R +4 more
europepmc +5 more sources
Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. [PDF]
Virology, 2018 HIV latency in resting CD4+ T cell represents a key barrier preventing cure of the infection with antiretroviral drugs alone. Latency reversing agents (LRAs) can activate HIV expression in latently infected cells, potentially leading to their elimination through virus-mediated cytopathic effects, host immune responses, and/or therapeutic strategies ...
Marsden MD +11 more
europepmc +7 more sources
Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design. [PDF]
JCI Insight, 2018 HIV eradication studies have focused on developing latency-reversing agents (LRAs). However, it is not understood how the rate of latent reservoir reduction is affected by different steps in the process of latency reversal. Furthermore, as current LRAs are host-directed, LRA treatment is likely to be intermittent to avoid host toxicities.
Ke R +3 more
europepmc +6 more sources
Defining the Effects of PKC Modulator HIV Latency-Reversing Agents on Natural Killer Cells [PDF]
Pathogens and ImmunityBackground: Latency reversing agents (LRAs) such as protein kinase C (PKC) modulators can reduce rebound-competent HIV reservoirs in small animal models.
Melanie Dimapasoc +8 more
doaj +4 more sources
Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents [PDF]
Journal of Infectious Diseases, 2017 Quiescent proviral genomes that persist during human immunodeficiency virus type 1 (HIV-1) infection despite effective antiretroviral therapy (ART) can fuel rebound viremia after ART interruption and is a central obstacle to the cure of HIV infection ...
, Nancie M Archin, Margolis David M
exaly +4 more sources
NSC95397 Is a Novel HIV-1 Latency-Reversing Agent [PDF]
Viruses, 2023 The latent viral reservoir represents one of the major barriers to curing HIV-1. Focus on the “kick and kill” (also called “shock and kill”) approach, in which virus expression is reactivated, and then cells producing virus are selectively depleted, has led to the discovery of many latency-reversing agents (LRAs) that have furthered our understanding ...
Randilea Nichols Doyle +5 more
openaire +7 more sources
Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency [PDF]
International Journal of Molecular Sciences, 2021 The ‘shock-and-kill’ strategy to purge the latent HIV reservoir relies on latency-reversing agents (LRAs) to reactivate the provirus and subsequent immune-mediated killing of HIV-expressing cells.
Daniela Angela Covino, Margherita Doria
exaly +3 more sources